Current Approaches in Diagnosis and Treatment in Ocular Oncology
Özet
Referanslar
Shields CL, Shields JA. Intraocular Tumors: An Atlas and Textbook. 3rd ed. Philadelphia: Wolters Kluwer; 2016.
Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye (Lond). 2017;31:241–257.
Singh AD, Rennie IG, Kivelä T. The Zimmerman-McLean-Foster hypothesis: 25 years later. Br J Ophthalmol. 2015;99:148–150.
Harbour JW, Chen R. The biology of uveal melanoma. Dev Ophthalmol. 2016;55:71–89.
Finger PT. New diagnostic and therapeutic trends in ocular oncology. Surv Ophthalmol. 2019;64:593–607.
WHO Classification of Tumours Editorial Board. WHO Classification of Eye Tumours. 4th ed. Lyon: IARC; 2018.
Shields CL, Pellegrini M, Ferenczy SR, et al. Enhanced depth imaging optical coherence tomography of intraocular tumors. Ophthalmology. 2014;121:1659–1670.
Mashayekhi A, Shields CL. Optical coherence tomography angiography in ocular oncology. Retina. 2019;39:204–213.
Mafee MF, Karimi A. Imaging of orbital tumors and tumor-like lesions. Radiol Clin North Am. 2017;55:87–105.
Walter SD, Chao DL, Feuer W, et al. Prognostic implications of tumor diameter in association with gene expression profile for uveal melanoma. JAMA Ophthalmol. 2016;134:734–740.
Fabian ID, Onadim Z, Karaa E, et al. The management of retinoblastoma. Oncogene. 2018;37:1551–1560.
Damato B, Kacperek A, Errington D, et al. Proton beam radiotherapy of uveal melanoma. Eye (Lond). 2015;29:12–22.
Mishra KK, Daftari IK. Stereotactic radiotherapy in ocular tumors. Semin Ophthalmol. 2016;31:95–103.
Carvajal RD, Piperno-Neumann S, Kapiteijn E, et al. Tebentafusp in metastatic uveal melanoma. N Engl J Med. 2022;386:1870–1881.
Khoja L, Atenafu EG, Suciu S, et al. Meta-analysis in metastatic uveal melanoma treated with immune checkpoint inhibitors. Cancer Med. 2019;8:708–714.
Referanslar
Shields CL, Shields JA. Intraocular Tumors: An Atlas and Textbook. 3rd ed. Philadelphia: Wolters Kluwer; 2016.
Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye (Lond). 2017;31:241–257.
Singh AD, Rennie IG, Kivelä T. The Zimmerman-McLean-Foster hypothesis: 25 years later. Br J Ophthalmol. 2015;99:148–150.
Harbour JW, Chen R. The biology of uveal melanoma. Dev Ophthalmol. 2016;55:71–89.
Finger PT. New diagnostic and therapeutic trends in ocular oncology. Surv Ophthalmol. 2019;64:593–607.
WHO Classification of Tumours Editorial Board. WHO Classification of Eye Tumours. 4th ed. Lyon: IARC; 2018.
Shields CL, Pellegrini M, Ferenczy SR, et al. Enhanced depth imaging optical coherence tomography of intraocular tumors. Ophthalmology. 2014;121:1659–1670.
Mashayekhi A, Shields CL. Optical coherence tomography angiography in ocular oncology. Retina. 2019;39:204–213.
Mafee MF, Karimi A. Imaging of orbital tumors and tumor-like lesions. Radiol Clin North Am. 2017;55:87–105.
Walter SD, Chao DL, Feuer W, et al. Prognostic implications of tumor diameter in association with gene expression profile for uveal melanoma. JAMA Ophthalmol. 2016;134:734–740.
Fabian ID, Onadim Z, Karaa E, et al. The management of retinoblastoma. Oncogene. 2018;37:1551–1560.
Damato B, Kacperek A, Errington D, et al. Proton beam radiotherapy of uveal melanoma. Eye (Lond). 2015;29:12–22.
Mishra KK, Daftari IK. Stereotactic radiotherapy in ocular tumors. Semin Ophthalmol. 2016;31:95–103.
Carvajal RD, Piperno-Neumann S, Kapiteijn E, et al. Tebentafusp in metastatic uveal melanoma. N Engl J Med. 2022;386:1870–1881.
Khoja L, Atenafu EG, Suciu S, et al. Meta-analysis in metastatic uveal melanoma treated with immune checkpoint inhibitors. Cancer Med. 2019;8:708–714.
